New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.
Interested in learning more about this Devex member? With a Recruitment Account, you can view the full profile & CV for this member and other professionals around the world. Click here to know more!
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $25.57. Pick the best stocks and ...
In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s shares closed yesterday at $301.44. According to TipRanks ...